Key result
Elevated baseline D-dimer independently predicted the development of cancer therapeutics-related cardiac dysfunction in patients undergoing cardiotoxic chemotherapy.
Why the study?
D-dimer is a sensitive biomarker for cancer-associated thrombosis, but little is known about its significance in cancer therapeutics-related cardiac dysfunction.
Does elevated baseline D-dimer predict the development of cancer therapeutics-related cardiac dysfunction in patients treated with cardiotoxic chemotherapy?
Cohort (n=169)
No
Does elevated baseline D-dimer predict the development of cancer therapeutics-related cardiac dysfunction in patients treated with cardiotoxic chemotherapy?
Elevated baseline D-dimer (>1.65 µg/ml) is an independent predictor of cancer therapeutics-related cardiac dysfunction in patients undergoing cardiotoxic chemotherapy.
Answers are grounded in this paper and cite their sources.
Elevated D-dimer may flag higher CTRCD risk during chemotherapy; leaves open whether serial monitoring improves outcomes.
Background: D-dimer is a sensitive biomarker for cancer-associated thrombosis, but little is known about its significance on cancer therapeutics-related cardiac dysfunction (CTRCD). Methods: Consecutive 169 patients planned for cardiotoxic chemotherapy were enrolled and followed up for 12 months. All patients underwent echocardiography and blood test at baseline, as well as at 3-month, 6-month, and 12-month. Results: The patients were divided into 2 groups based on the level of D-dimer (> 1.65 µg/ml or ≦ 1.65 µg/ml) at baseline before chemotherapy: High D-dimer group (n = 37) and low D-dimer group (n = 132). Left ventricular ejection fraction (EF) decreased at 3-month and 6-month after chemotherapy in high D-dimer group (baseline, 65.2% [62.8%-71.4%]; 3-month, 62.9% [59.0%-67.7%]; 6-month, 63.1% [60.0%-67.1%]; 12-month, 63.3% [58.8%-66.0%], P = 0.03), but no change was observed in low D-dimer group. The occurrence of CTRCD within the 12-month follow-up period was higher in high D-dimer group than in low D-dimer group (16.2% vs. 4.5%, P = 0.0146). Multivariable logistic regression analysis revealed that high D-dimer level at baseline was an independent predictor of the development of CTRCD (odds ratio 3.93, 95% CI [1.00-15.82], P = 0.047). Conclusion: Elevated D-dimer is a pivotal biomarker to predict CTRCD.
No takes yet. Share an insight, caveat, or question.
Oikawa et al. (2021) conducted a cohort in Cancer therapeutics-related cardiac dysfunction (CTRCD) (n=169). Elevated baseline D-dimer (> 1.65 µg/ml) vs. Low baseline D-dimer (≦ 1.65 µg/ml) was evaluated on Occurrence of cancer therapeutics-related cardiac dysfunction (CTRCD) within 12 months (OR 3.93, 95% CI 1.00-15.82, p=0.047). Elevated baseline D-dimer independently predicted the development of cancer therapeutics-related cardiac dysfunction in patients undergoing cardiotoxic chemotherapy.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: